Table 5.
Comparison of Objective Response Rate (ORR) Between/Among Subgroups Divided by Demographic and Clinical Characteristics
| Parameters | N | Not ORR | ORR | p Value |
|---|---|---|---|---|
| Age | 0.185 | |||
| >60 years (n/%) | 122 | 24 (19.7) | 98 (80.3) | |
| <60 years (n/%) | 153 | 21 (13.7) | 132 (86.3) | |
| Gender | 0.765 | |||
| Male (n/%) | 228 | 38 (16.7) | 190 (83.3) | |
| Female (n/%) | 47 | 7 (14.9) | 40 (85.1) | |
| History of HB | 0.062 | |||
| Yes (n/%) | 228 | 33 (14.5) | 195 (85.5) | |
| No (n/%) | 47 | 12 (25.5) | 35 (74.5) | |
| History of alcohol use | 0.573 | |||
| Yes (n/%) | 130 | 23 (17.7) | 107 (82.3) | |
| No (n/%) | 145 | 22 (15.2) | 123 (84.8) | |
| History of cirrhosis | 0.318 | |||
| Yes (n/%) | 165 | 24 (14.5) | 141 (85.5) | |
| No (n/%) | 110 | 21 (19.1) | 89 (80.9) | |
| Tumor distribution | 0.057 | |||
| Multifocal disease (n/%) | 180 | 35 (19.4) | 145 (80.6) | |
| Unifocal disease (n/%) | 95 | 10 (10.5) | 85 (89.5) | |
| Tumor location | 0.835 | |||
| Left liver (n/%) | 42 | 8 (19.0) | 34 (81.0) | |
| Right liver (n/%) | 144 | 22 (15.3) | 122 (84.7) | |
| Bilobar (n/%) | 89 | 15 (16.9) | 74 (83.1) | |
| Largest nodule size | 0.722 | |||
| ≥5 cm (n/%) | 135 | 21 (15.6) | 114 (84.4) | |
| <5 cm (n/%) | 140 | 24 (17.1) | 116 (82.9) | |
| Portal vein invasion | 0.019 | |||
| Yes (n/%) | 82 | 20 (24.4) | 62 (75.6) | |
| No (n/%) | 193 | 25 (13.0) | 168 (87.0) | |
| Hepatic vein invasion | 0.159 | |||
| Yes (n/%) | 37 | 9 (24.3) | 28 (75.7) | |
| No (n/%) | 238 | 36 (15.1) | 202 (84.9) | |
| ECOG performance status | 0.788 | |||
| 0 (n/%) | 172 | 29 (16.9) | 143 (83.1) | |
| 1 (n/%) | 83 | 13 (15.7) | 70 (84.3) | |
| 2 (n/%) | 14 | 1 (7.1) | 13 (92.9) | |
| 3 (n/%) | 6 | 2 (33.3) | 4 (66.7) | |
| Child–Pugh stage | 0.914 | |||
| A (n/%) | 228 | 37 (16.2) | 191 (83.8) | |
| B (n/%) | 45 | 8 (17.8) | 37 (82.2) | |
| C (n/%) | 2 | 0 (0) | 2 (100) | |
| BCLC stage | 0.538 | |||
| 0 (n/%) | 1 | 0 (0) | 1 (100) | |
| A (n/%) | 67 | 10 (14.9) | 57 (85.1) | |
| B (n/%) | 108 | 17 (15.7) | 91 (84.3) | |
| C (n/%) | 98 | 18 (18.4) | 80 (81.6) | |
| D (n/%) | 1 | 0 (0) | 1 (100) | |
| Cycles of DEB-TACE treatment | 0.426 | |||
| One cycle (n/%) | 227 | 39 (17.2) | 188 (82.8) | |
| Two or more cycles (n/%) | 48 | 6 (12.5) | 42 (87.5) | |
| Previous cTACE treatment | 0.061 | |||
| Yes (n/%) | 118 | 25 (21.2) | 93 (78.8) | |
| No (n/%) | 157 | 20 (12.7) | 137 (87.3) | |
| Previous surgery | 0.278 | |||
| Yes (n/%) | 68 | 14 (20.6) | 54 (79.4) | |
| No (n/%) | 207 | 31 (15.0) | 176 (85.0) | |
| Previous systematic chemotherapy | 0.101 | |||
| Yes (n/%) | 8 | 3 (37.5) | 5 (62.5) | |
| No (n/%) | 267 | 42 (15.7) | 225 (84.3) | |
| Previous radiofrequency ablation | 0.308 | |||
| Yes (n/%) | 36 | 8 (22.2) | 28 (77.8) | |
| No (n/%) | 239 | 37 (15.5) | 202 (84.5) | |
| Previous targeted therapy | 0.361 | |||
| Yes (n/%) | 8 | 0 (0) | 8 (100) | |
| No (n/%) | 267 | 45 (16.9) | 222 (83.1) | |
| Combination of ordinary embolization agent | 0.254 | |||
| Yes (n/%) | 100 | 13 (13.0) | 87 (87.0) | |
| No (n/%) | 175 | 32 (18.3) | 143 (81.7) |
Data are presented as count (%). Comparison between two groups was determined by chi-square test. A value of p < 0.05 was considered significant.